Published in Pattern Recognit on June 01, 2009
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun (2014) 4.16
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med (2011) 3.66
Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 3.56
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med (2012) 2.65
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging (2012) 2.31
Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity. Eur J Nucl Med Mol Imaging (2013) 2.09
Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. Acta Oncol (2010) 1.92
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging (2012) 1.75
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Robust Radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One (2014) 1.49
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2013) 1.33
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.33
Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging (2013) 1.26
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer. Sci Rep (2015) 1.21
The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med (2013) 1.14
Reply to: Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity. Eur J Nucl Med Mol Imaging (2013) 1.11
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. Nucl Med Mol Imaging (2014) 1.08
The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep (2015) 1.08
Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur J Nucl Med Mol Imaging (2016) 1.07
Quantitative radiomics: impact of stochastic effects on textural feature analysis implies the need for standards. J Med Imaging (Bellingham) (2015) 0.99
Predicting future morphological changes of lesions from radiotracer uptake in 18F-FDG-PET images. PLoS One (2013) 0.99
Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. PLoS One (2014) 0.97
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. J Magn Reson Imaging (2015) 0.96
False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review. PLoS One (2015) 0.96
The age of reason for FDG PET image-derived indices. Eur J Nucl Med Mol Imaging (2012) 0.96
Quantification of heterogeneity observed in medical images. BMC Med Imaging (2013) 0.94
On some misconceptions about tumor heterogeneity quantification. Eur J Nucl Med Mol Imaging (2013) 0.94
Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging (2015) 0.92
Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns. Med Phys (2013) 0.91
Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology (2016) 0.91
Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer. PLoS One (2014) 0.90
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front Med (Lausanne) (2015) 0.89
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation. Mol Imaging Biol (2016) 0.89
Variability of Image Features Computed from Conventional and Respiratory-Gated PET/CT Images of Lung Cancer. Transl Oncol (2015) 0.88
Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol (2012) 0.87
Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study. Radiat Oncol (2015) 0.87
FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging (2016) 0.86
Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. J Gynecol Oncol (2016) 0.85
Applications and limitations of radiomics. Phys Med Biol (2016) 0.85
Development and evaluation of an open-source software package "CGITA" for quantifying tumor heterogeneity with molecular images. Biomed Res Int (2014) 0.84
Texture analysis of (18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging (2016) 0.84
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol (2013) 0.83
PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging (2015) 0.83
The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning. Br J Radiol (2014) 0.82
Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS One (2015) 0.81
Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. J Nucl Med (2016) 0.81
18F-FDG PET-Derived Textural Indices Reflect Tissue-Specific Uptake Pattern in Non-Small Cell Lung Cancer. PLoS One (2015) 0.81
Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol (2014) 0.81
FDG uptake heterogeneity in FIGO IIb cervical carcinoma does not predict pelvic lymph node involvement. Radiat Oncol (2013) 0.81
Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma. AJNR Am J Neuroradiol (2013) 0.81
(18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. Eur J Nucl Med Mol Imaging (2016) 0.80
Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. Eur Radiol (2015) 0.80
Differentiation of Benign Fluid Collections from Soft-Tissue Sarcomas on FDG-PET/CT. J Cancer (2014) 0.80
Automatic Segmentation of Lung Carcinoma Using 3D Texture Features in 18-FDG PET/CT. Int J Mol Imaging (2013) 0.80
Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR. Br J Radiol (2015) 0.80
Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev (2016) 0.80
State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol (2015) 0.80
PETSTEP: Generation of synthetic PET lesions for fast evaluation of segmentation methods. Phys Med (2015) 0.79
Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer. Eur Radiol (2016) 0.79
Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. Int J Radiat Oncol Biol Phys (2016) 0.79
Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity: further comments. Eur J Nucl Med Mol Imaging (2013) 0.79
Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. Tomography (2016) 0.79
Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. Clin Nucl Med (2017) 0.78
Exploring the use of shape and texture descriptors of positron emission tomography tracer distribution in imaging studies of neurodegenerative disease. J Cereb Blood Flow Metab (2015) 0.78
Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol (2016) 0.78
Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One (2016) 0.78
Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. World J Radiol (2016) 0.78
Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials. PLoS One (2016) 0.78
The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging (2016) 0.78
Low-order non-spatial effects dominate second-order spatial effects in the texture quantifier analysis of 18F-FDG-PET images. PLoS One (2015) 0.77
Computerized PET/CT image analysis in the evaluation of tumour response to therapy. Br J Radiol (2015) 0.77
A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. Phys Med Biol (2015) 0.77
Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. Br J Cancer (2015) 0.77
Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer (2014) 0.77
Respiration-Averaged CT for Attenuation Correction of PET Images - Impact on PET Texture Features in Non-Small Cell Lung Cancer Patients. PLoS One (2016) 0.77
Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. Neuroimage Clin (2016) 0.76
Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Oncotarget (2016) 0.75
PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2011) 0.75
Positron emission tomography/computerized tomography for tumor response assessment-a review of clinical practices and radiomics studies. Transl Cancer Res (2016) 0.75
A new assessment model for tumor heterogeneity analysis with [18]F-FDG PET images. EXCLI J (2016) 0.75
Value of (18)F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. Br J Radiol (2016) 0.75
Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment. Phys Med Biol (2011) 0.75
A method for comparing intra-tumoural radioactivity uptake heterogeneity in preclinical positron emission tomography studies. EJNMMI Phys (2015) 0.75
Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier. PLoS One (2017) 0.75
Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer. Transl Oncol (2017) 0.75
Effects of reusing baseline volumes of interest by applying (non-)rigid image registration on positron emission tomography response assessments. PLoS One (2014) 0.75
Quality of Radiomic Features in Glioblastoma Multiforme: Impact of Semi-Automated Tumor Segmentation Software. Korean J Radiol (2017) 0.75
Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol (2017) 0.75
Multiple comparisons permutation test for image based data mining in radiotherapy. Radiat Oncol (2013) 0.75
Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open (2017) 0.75
Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med Imaging (2017) 0.75
The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. Eur Radiol (2017) 0.75
A pilot study for texture analysis of (18)F-FDG and (18)F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery. Eur J Nucl Med Mol Imaging (2017) 0.75
The diagnostic ability of (18)F-FDG PET/CT for mediastinal lymph node staging using (18)F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer. Eur Radiol (2016) 0.75
Textural features of (18)F-fluorodeoxyglucose positron emission tomography scanning in diagnosing aortic prosthetic graft infection. Eur J Nucl Med Mol Imaging (2016) 0.75
Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget (2017) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
CERR: a computational environment for radiotherapy research. Med Phys (2003) 5.62
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med (2005) 3.26
The applications of PET in clinical oncology. J Nucl Med (1991) 3.11
Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys (2004) 2.93
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.55
Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys (2005) 1.89
Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 1.85
A support vector machine approach for detection of microcalcifications. IEEE Trans Med Imaging (2002) 1.82
Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys (2006) 1.79
FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck (2002) 1.66
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys (2004) 1.64
Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys (2004) 1.64
Dose-volume histograms. Int J Radiat Oncol Biol Phys (1991) 1.62
Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET. Biostatistics (2005) 1.44
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med (2006) 1.43
Gradient and texture analysis for the classification of mammographic masses. IEEE Trans Med Imaging (2000) 1.33
A CAD system for the automatic detection of clustered microcalcifications in digitized mammogram films. IEEE Trans Med Imaging (2000) 1.33
A statistical measure of tissue heterogeneity with application to 3D PET sarcoma data. Biostatistics (2003) 1.32
Concurrent multimodality image segmentation by active contours for radiotherapy treatment planning. Med Phys (2007) 1.26
Complexity curve and grey level co-occurrence matrix in the texture evaluation of breast tumor on ultrasound images. Med Phys (2007) 1.23
Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys (2004) 1.11
2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res (2007) 1.05
F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol (2005) 1.05
Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol (2004) 1.04
Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol (1998) 1.02
Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med (2003) 1.00
FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.91
A technique for computing dose volume histograms for structure combinations. Med Phys (1988) 0.88
PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys (2003) 0.87
Regarding Davis et al.: Assessment of (18)F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol (2007) 0.84
FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer (2006) 0.84
Texture analysis of differently reconstructed PET images. Phys Med Biol (1996) 0.83
Positron-emission tomography for head and neck cancer. Semin Radiat Oncol (2004) 0.83
Mitochondrial origins. Proc Natl Acad Sci U S A (1985) 8.82
Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature (1996) 7.27
A phylogenetic analysis of the mycoplasmas: basis for their classification. J Bacteriol (1989) 6.66
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med (2005) 4.79
Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys (1994) 4.50
The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci U S A (2000) 3.16
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys (2001) 2.85
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol (2000) 2.70
Human beta-defensins. Cell Mol Life Sci (2006) 2.57
Enalapril induced persistent hypotension and acute renal failure. J Assoc Physicians India (1991) 2.49
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
MicroRT-small animal conformal irradiator. Med Phys (2007) 2.46
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol (2010) 2.39
Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol (2000) 2.35
Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science (1988) 2.35
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
A dedicated cone-beam CT system for musculoskeletal extremities imaging: design, optimization, and initial performance characterization. Med Phys (2011) 2.20
Repair of a specific double-strand break generated within a mammalian chromosome by yeast endonuclease I-SceI. Nucleic Acids Res (1994) 2.17
[Effect of intraocular pressure on glaucomatous damage to the optic nerve]. Ophthalmologe (2014) 2.15
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
Influence of Nitrate and Ammonia on Photosynthetic Characteristics and Leaf Anatomy of Moricandia arvensis. Plant Physiol (1982) 2.02
Transillumination-assisted orotracheal intubation: a comparison of the Bonfils fibrescope and the lightwand (Trachlight). Acta Anaesthesiol Scand (2012) 2.02
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Gold nanocages as photothermal transducers for cancer treatment. Small (2010) 1.92
Registration of [18F]FDG microPET and small-animal MRI. Nucl Med Biol (2005) 1.89
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Sinoatrial node pacemaker activity requires Ca(2+)/calmodulin-dependent protein kinase II activation. Circ Res (2000) 1.85
Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol (2000) 1.79
Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A (1997) 1.76
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst (2001) 1.71
[Reliable micromethod for determination of the protein content in tissue homogenates]. Acta Biol Med Ger (1975) 1.69
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 1.66
Clostridium ljungdahlii sp. nov., an acetogenic species in clostridial rRNA homology group I. Int J Syst Bacteriol (1993) 1.65
Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem (1994) 1.63
Sleepless in surbiton. Br Dent J (2005) 1.62
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol (2009) 1.58
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res (2001) 1.55
Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol (2001) 1.55
Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene (2001) 1.54
Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes (2001) 1.54
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2008) 1.51
The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol (2000) 1.50
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res (1997) 1.50
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer (2012) 1.49
Global folds of proteins with low densities of NOEs using residual dipolar couplings: application to the 370-residue maltodextrin-binding protein. J Mol Biol (2000) 1.48
Minimally invasive method of determining blood input function from PET images in rodents. J Nucl Med (2006) 1.46
Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis (2003) 1.46
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships. Phys Med Biol (2006) 1.44
Orienting domains in proteins using dipolar couplings measured by liquid-state NMR: differences in solution and crystal forms of maltodextrin binding protein loaded with beta-cyclodextrin. J Mol Biol (2000) 1.43
Prevalence of abdominal aortic aneurysms in men with diabetes. Med J Aust (1997) 1.42
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol (1995) 1.42
Percutaneous vasal sperm aspiration and intrauterine insemination in the treatment of obstructive azoospermia. Fertil Steril (1997) 1.41
Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol (1998) 1.41
Human DNA polymerase kappa synthesizes DNA with extraordinarily low fidelity. Nucleic Acids Res (2000) 1.41
Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood (2000) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Instrumentation aspects of animal PET. Annu Rev Biomed Eng (2005) 1.40
Isolated spastic paraparesis leading to diagnosis of Friedreich's ataxia. J Neurol Neurosurg Psychiatry (2000) 1.40
Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol (2001) 1.40
Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett (1994) 1.39
NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med (2012) 1.38
The effect of ondansetron and intrathecal diamorphine on length of stay after caesarean section: an impact audit cycle. Anaesthesia (2013) 1.38
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
A review of parameters for the bioelectrical characterization of breast tissue. Ann N Y Acad Sci (1999) 1.34
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest (1995) 1.29
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem (1991) 1.29
Self-care strategies for symptom management in patients with chronic heart failure. Nurs Res (2000) 1.27
Urinary magnesium, calcium, and phosphate excretion during magnesium sulfate infusion. Obstet Gynecol (1981) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2000) 1.26
18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med (2007) 1.25
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25
Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 A determined from the single-wavelength anomalous scattering signal of an incorporated iodine atom. Proc Natl Acad Sci U S A (1991) 1.24
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol (2008) 1.24
Review: modulating factors in amyloid-beta fibril formation. J Struct Biol (2000) 1.23